Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Delphine SculierGilles WandelerSabine YerlyAnnalisa MarinosciMarcel StoeckleEnos BernasconiDominique L BraunPietro VernazzaMatthias CavassiniMarta BuzziKarin J MetznerLaurent Arthur DecosterdHuldrych F GunthardPatrick SchmidAndreas LimacherMatthias EggerAlexandra Calmynull nullPublished in: PLoS medicine (2020)
ClinicalTrials.gov NCT03160105.